01 Oct 2026 Recon: Sanofi, Regeneron expand partnership after Dupixent success; Lilly amylin-Zepbound combo succeeds in mid-stage trial Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
29 Sep 2026 Recon: FDA approves Egetis’ Emcitate for rare genetic disease; Novo buys rights to Chinese weight-loss pill in $2.6B deal Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
28 Sep 2026 Recon: FDA approves drugs for Parkinson’s, bile duct cancer, rare soft tissue disease; Merck, Daiichi scrap application for ADC in lung cancer Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
24 Sep 2026 Recon: Adcomm backs Grail’s cancer test; Lilly, China’s InnoCare sign $3.35B deal Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
22 Sep 2026 Recon: Pharma companies urge Trump administration to protect China deals; EU drugmakers seek faster trials, more spending to compete with US, China Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
21 Sep 2026 Recon: FDA staff raise no major concerns for Grail multi-cancer test ahead of adcomm; Trump admin drafting order to exert control over NIH grant funding Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
17 Sep 2026 Recon: Senate hearing set for FDA nominee; Novo partners with Anthropic for AI drug development Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
15 Sep 2026 Recon: Experts press FDA to set safety, access standards for psychedelic drugs; GSK to shut German vaccine factory due to low demand Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
14 Sep 2026 Recon: New FDA oncology chief vows continued innovation in OCE; FDA approves drugs for two rare genetic diseases Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
10 Sep 2026 Recon: UK unveils recommendations for regulating AI in medicine; FDA halts new enrollment in Biohaven epilepsy trials Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
